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O R I G I N A L  A R T I C L E
ataract is a common, vision-altering condition that 
affects 36 million people in Western Europe and is 
projected to affect approximately 30 million peo-
ple in the United States by the year 2020.1 Implantation of 
a monofocal intraocular lens (IOL) after surgical removal of 
cataract via phacoemulsification is the standard of care in the 
Western world.2 Although monofocal IOLs result in excellent 
distance acuity, patients usually require corrective spectacles 
CABSTRACTPURPOSE: To evaluate visual outcomes, spectacle 
independence, and quality of life among nonastig-
matic and astigmatic patients who received AcrySof IQ 
ReSTOR toric or nontoric multifocal intraocular lenses 
(IOLs) (Alcon Laboratories, Fort Worth, TX) compared 
with those who received commercially available nontoric 
monofocal IOLs after bilateral cataract removal.
METHODS: This randomized, patient- and observer-
technician–masked study was conducted at 20 sites in 
Europe. Patients were randomized to receive monofocal 
(nontoric only) or multifocal (nontoric or toric, as need-
ed) IOLs. Primary efficacy endpoints included percent-
age of patients achieving binocular uncorrected distance 
and near acuity of 0.1 logMAR or better (20/25 Snellen), 
spectacle independence, and scores on the National Eye 
Institute Refractive Error and Quality of Life questionnaire 
domains. Safety endpoints included adverse events and 
refractive error within 0.5 and 1.0 diopters. 
RESULTS: In the multifocal group (n = 108) versus the 
monofocal group (n = 100), significantly more patients 
achieved uncorrected distance and near acuity of 0.1 
logMAR or better (45.7% vs 2.1%; P < .0001) and 
spectacle independence (73.3% vs 25.3%; P < .0001) 
at 6 months. The percentage of patients who achieved 
uncorrected distance visual acuity of 20/40 or better at 
6 months was 92% in the multifocal group and 97% in 
the monofocal group. National Eye Institute Refractive 
Error and Quality of Life scores were significantly better 
for dependence on correction in the multifocal group 
(P < .0001) and for glare in the monofocal group (P 
= .0157); other domain scores were similar between 
groups. No significant trends in study device-related ad-
verse events were observed.
CONCLUSIONS: Monofocal and multifocal IOLs pro-
vided good clinical outcomes. More patients receiving 
multifocal IOLs attained better uncorrected visual acu-
ity at a range of distances and spectacle independence 
compared with patients who received monofocal IOLs. 
Monofocal IOLs were associated with better patient-
reported scores for glare compared with multifocal IOLs; 
however, scores for patient satisfaction were significantly 
better in the multifocal group.
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for vision at near and intermediate distances and resid-
ual astigmatic error, if any.3,4 Astigmatism should be 
managed during cataract surgery and IOL implantation 
to minimize postoperative dependence on spectacles.5 
Incomplete restoration of visual acuity in patients im-
planted with monofocal or multifocal IOLs has been 
associated with limiting factors contributing to quality 
of life, such as reading and maintaining hobbies that 
require near vision.6 
Multifocal IOLs could decrease patients’ need for 
spectacles by providing good vision across a range of 
distances (near, intermediate, and far). Newer multifo-
cal IOL designs improve patient vision and achieve ac-
ceptable patient satisfaction.7 The AcrySof IQ ReSTOR 
(Alcon Laboratories, Fort Worth, TX) is a commercially 
available multifocal IOL for primary implantation in 
the capsular bag of the eye for visual correction of 
aphakia secondary to removal of a cataractous lens.8-10 
This IOL combines a central apodized diffractive re-
gion for enhanced near vision, surrounded by a refrac-
tive region for distance vision. The AcrySof IQ Re-
STOR toric IOL is a multifocal IOL that can address 
corneal astigmatism.5 
The goal of this study was to evaluate and compare 
visual outcomes, spectacle independence, and patient 
vision-related quality of life following bilateral im-
plantation of either commercially available monofocal 
IOLs or AcrySof IQ ReSTOR multifocal IOLs among 
patients undergoing cataract surgery.
PATIENTS AND METHODS
Study deSign
This was a phase 4 prospective, randomized, 
patient- and observer-technician–masked, compara-
tive, 6-month follow-up study conducted in 20 centers 
in France, Germany, Italy, the Netherlands, Spain, and 
the United Kingdom between April 2011 and October 
2012 (ClinicalTrials.gov Identifier: NCT01290068). 
The study protocol was approved by the ethics com-
mittees of all study centers, and the study was per-
formed in compliance with the tenets of the Declara-
tion of Helsinki. Informed consent was provided by all 
patients before study entry.
PatientS
Study participants, aged 21 years or older, were previ-
ously diagnosed as having bilateral age-related cataracts 
and planned cataract removal using phacoemulsifica-
tion with subsequent IOL implantation. Eligible patients 
were either nonastigmatic or were astigmatic with pre-
operative regular corneal astigmatism of 2.5 diopters (D) 
or less, with otherwise healthy eyes, and were available 
to undergo cataract removal in the second eye 6 weeks 
or less after the first eye surgery. Additionally, it was re-
quired that both eyes meet qualification criteria for on-
label implantation of the AcrySof IQ ReSTOR family of 
IOLs. Key exclusion criteria included previous corneal 
surgery or corneal reshaping, corneal abnormalities, con-
ditions or diseases that contraindicated implantation of a 
toric IOL, or planned multiple procedures during phaco-
emulsification and IOL implantation surgery.
treatment
Patients were randomized to receive either AcrySof 
IQ ReSTOR multifocal IOLs (nontoric or toric as re-
quired) or commercially available monofocal IOLs 
(nontoric only) on the date of the first operative visit 
before surgery in the first eye to be treated; patients 
were to receive bilateral implantation of either multifo-
cal or monofocal aspheric IOLs. Patients in the multifo-
cal IOL group received toric or nontoric models based 
on the magnitude of preoperative corneal astigmatism; 
patients in the monofocal IOL group received nontoric 
IOLs only. A web-based calculator that accounted for 
predicted IOL power as evaluated by biometry, preop-
erative keratometric values, surgically induced astig-
matism, and incision placement was used to determine 
whether toric or nontoric IOLs were needed for patients 
receiving multifocal IOLs. If the calculator determined 
that a patient required a toric IOL, it also established 
the alignment. Cataract extraction and IOL implanta-
tion were performed according to the participating 
clinics’ standard methods. Postoperative medications 
were provided to all patients according to the clinics’ 
standard of care following routine cataract removal.
efficacy endPointS and aSSeSSmentS
The three primary efficacy endpoints were percentage 
of patients achieving binocular uncorrected distance visual 
acuity and uncorrected near visual acuity 0.1 logMAR or 
better (20/25 Snellen); spectacle independence (ie, not us-
ing or prescribed spectacles) at all distances; and National 
Eye Institute Refractive Error and Quality of Life instru-
ment score (NEI RQL-42; range: 0 to 100 [higher score indi-
cates a better outcome])11 in five dimensions: near vision, 
activity limitations, dependence on refractive correction 
(ie, glasses, bifocal lenses, magnifier, contact lenses),12 ap-
pearance, and satisfaction with correction. 
The secondary efficacy endpoint was the cost of 
spectacles. An additional eight nonprimary NEI RQL-
42 dimensions (clarity of vision, expectation, far vi-
sion, diurnal fluctuation, glare, symptoms [eg, burn-
ing, itching, aching, dryness],12 worry, and suboptimal 
correction) were assessed as exploratory endpoints. 
Visual acuity testing was performed at far (4 m), 
near (40 cm), and intermediate (60 cm) distances using 
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Early Treatment of Diabetic Retinopathy Study (ETDRS) 
charts at 100% contrast. Actual logMAR visual acuity 
was calculated using baseline logMAR visual acuity 
(the last line from which the patient correctly read 1 or 
more letters) and the number of letters read incorrectly. 
Lens information (model, diopter power, and serial 
number) was documented separately from case report 
forms and was masked throughout the study to pa-
tients and the observer-technicians who measured vi-
sual acuity and refraction. Ophthalmologists perform-
ing IOL implantation were not masked.
Safety aSSeSSmentS
The incidence rates of adverse events, including 
surgical reintervention such as IOL replacement, ex-
plantation, or repositioning, were recorded intraop-
eratively and at postoperative day 1 and months 1, 3, 
and 6. Achievement of postoperative refractive error 
greater than 0.50 D and greater than 1.0 D at 6 months 
was also assessed.
data analySiS and StatiSticS
Efficacy endpoints were analyzed in the intent-to-
treat population, defined as all patients who were ran-
domized to a treatment group and to whom the random-
ized IOL was presented or implanted during the first eye 
surgery. Patients in the intent-to-treat population were 
grouped according to the randomly assigned treatment 
group (ie, multifocal or monofocal IOL). The propor-
tion of patients achieving binocular uncorrected dis-
tance acuity and uncorrected near visual acuity of 0.1 
logMAR or better (20/25 Snellen) and the proportion of 
patients with spectacle independence in each group at 
the 6-month visit were compared using logistic regres-
sion models with binary response that included coun-
try, implantation group, and preoperative astigmatism 
as covariates. The NEI RQL-42 scores at the 6-month vis-
it for each group were compared using an analysis of co-
variance model with country, implantation group, pre-
operative astigmatism, and baseline dimension scores 
as covariates. Missing primary endpoint data were ac-
counted for using the last observation carried forward. 
The total cost of spectacles purchased (frames plus 
lenses) in all patients was compared between groups 
using a nonparametric Kolmogorov–Smirnov test. If 
total cost was missing for a spectacle-independent pa-
tient, 0 euros was imputed. If total cost was missing 
for a spectacle-dependent patient, the mean cost for 
all spectacle-dependent patients in that group was im-
puted. The summary statistics for spectacle-dependent 
patients were based on those spectacle-dependent pa-
tients who provided a cost or reimbursement amount. 
Analysis of the five primary NEI RQL-42 domains was 
performed using the Hommel multiple testing correc-
Figure 1. Patient disposition. AE = adverse 
event; IOL = intraocular lens; ITT = intent-
to-treat; monofocal IOL = commercially avail-
able nontoric IOLs; multifocal IOL = AcrySof 
IQ ReSTOR nontoric or toric IOLs (Alcon 
Laboratories, Fort Worth, TX).
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tion procedure. All statistical analyses were performed 
with two-sided tests at a significance level of 5%. 
Safety analyses were assessed in the safety popula-
tion, defined as all patients randomized to a treatment 
group who received one or more implanted IOL, and 
were coded using the Medical Dictionary for Regula-
tory Activities, version 14.0. Safety analysis was con-
ducted according to the received IOL implantation 
groups; for patients who received one multifocal IOL 
and one monofocal IOL, safety analysis was based on 
the planned implantation group. 
RESULTS
PatientS
A total of 208 patients were randomized (multi-
focal IOL group, n = 108; monofocal IOL group, n = 
100), 195 of whom completed the study (Figure 1). 
The safety and intent-to-treat populations each com-
prised 206 patients; treatment group sizes between 
safety and intent-to-treat populations varied because 
3 patients who were randomized to receive multifocal 
lenses received monofocal lenses, and 1 patient who 
was randomized to receive monofocal lenses received 
multifocal lenses. However, all patients were eligible 
for both multifocal and monofocal IOLs and were not 
informed of their randomization group before surgery. 
Of the patients who received multifocal lenses, 86 re-
ceived toric models and 19 received nontoric models. 
Patient age, sex, and race were similar between treat-
ment groups (Table 1).
efficacy
A significantly greater proportion of patients 
achieved both distance and near binocular uncorrected 
visual acuity (0.1 logMAR or better [20/25 Snellen] at 
the 6-month visit) in the multifocal IOL group (45.7%, 
n = 48/105) compared with the monofocal IOL group 
(2.1%, n = 2/97; odds ratio, 45.9 [95% confidence in-
terval, 10.5 to 200.8]; P < .0001; Figure 2). Uncorrected 
distance visual acuity of 20/40 or better at 6 months 
was achieved by 92% of patients in the multifocal 
IOL group and 97% of patients in the monofocal IOL 
TABLE 1
Patient Demographics, Intent-to-Treat Population
Characteristic Multifocal Group (n = 108) Monofocal Group (n = 98) Total (n = 206)
Mean ± standard deviation age, years 70.0 ± 8.3 70.8 ± 7.8 70.4 ± 8.1
Age category, n (%)
  21 to 59 years 13 (12.0) 7 (7.1) 20 (9.7)
  60 to 69 years 40 (37.0) 36 (36.7) 76 (36.9)
  70 to 79 years 40 (37.0) 45 (45.9) 85 (41.3)
  80 years or older 15 (13.9) 10 (10.2) 25 (12.1)
Sex, n (%)
  Male 45 (41.7) 40 (40.8) 85 (41.3)
  Female 63 (58.3) 58 (59.2) 121 (58.7)
Race, n (%)
  White 103 (95.4) 94 (95.9) 197 (95.6)
  Black or African American 1 (0.9) 2 (2.0) 3 (1.5)
  Asian 3 (2.8) 2 (2.0) 5 (2.4)
  American Indian or Alaska Native 1 (0.9) 0 1 (0.5)
Monofocal group = commercially available nontoric monofocal intraocular lens group; multifocal group = AcrySof IQ ReSTOR or AcrySof IQ ReSTOR toric intraocu-
lar lens (Alcon Laboratories, Fort Worth, TX) group.
Figure 2. Percentages of patients who achieved binocular uncorrected 
distance and binocular uncorrected near visual acuity 0.1 logMAR or 
better (20/25 Snellen) and percentages of patients who were spectacle 
free at 6 months postoperatively. IOL = intraocular lens; monofocal IOL = 
commercially available nontoric IOLs; multifocal IOL = AcrySof IQ ReSTOR 
nontoric or toric IOLs (Alcon Laboratories, Fort Worth, TX).
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group. The number of patients with spectacle inde-
pendence at 6 months was significantly higher in the 
multifocal IOL group than in the monofocal IOL group 
(73.3% [n = 74 of 101] vs 25.3% [n = 24 of 95], respec-
tively; odds ratio, 10.2 [95% confidence interval, 5.0 to 
20.8; P < .0001; Figure 2). At 6 months, scores on the 
NEI RQL-42 survey for dependence on correction were 
significantly better in the multifocal IOL group (least 
squares mean ± standard error, 83.7 ± 3.5) compared 
with the monofocal IOL group (46.3 ± 3.7; P < .0001). 
Scores were similar between treatment groups for the 
domains of near vision, activity limitations, appear-
ance, and satisfaction with correction (Table 2). 
The total cost of spectacles, the secondary endpoint, 
was significantly lower in the multifocal IOL group than 
in the monofocal IOL group (P < .0001; Kolmogorov–
Smirnov test statistic, 0.49; Table A, available in the on-
line version of this article). Total spectacle cost among 
all evaluable patients, including those who were spec-
tacle independent, and in spectacle-dependent patients 
who reported spectacle cost information, was lower in 
the multifocal IOL group compared with the monofocal 
IOL group (Table A). The individual costs of lenses and 
frames were also lower with multifocal versus monofo-
cal IOLs (Table A). Long-term costs were not determined.
Among the eight nonprimary NEI RQL-42 dimen-
sions assessed as exploratory endpoints, patient scores 
for diurnal fluctuations, symptoms, worry, clarity of vi-
sion, far vision, and suboptimal correction were similar 
between groups. Scores (least squares mean ± standard 
error) for patient expectations were significantly better 
in the multifocal IOL group (69.1 ± 4.0) compared with 
the monofocal IOL group (54.2 ± 4.3; P < .01; Table 2). 
Scores on the glare dimension were significantly bet-
ter in the monofocal IOL group (78.5 ± 3.3) than in the 
multifocal IOL group (69.0 ± 3.1) (P < .05).
Safety
Treatment-emergent adverse events were reported 
for 40.6% (43 of 106) of patients in the multifocal IOL 
group and for 30.0% (30 of 100) of patients in the mono-
focal IOL group (Table B, available in the online ver-
sion of this article). With the exception of two events 
(right and left eye) of photophobia reported in 1 patient 
in the monofocal IOL group, adverse events and seri-
ous adverse events were considered to be unrelated to 
the study devices. Posterior capsule opacification was 
observed in 5 patients who received multifocal IOLs 
and in 3 patients who received monofocal IOLs; surgi-
cal reintervention (ie, YAG capsulotomy) was required 
for 3 eyes in the multifocal IOL group. The optic disc 
edge of the multifocal and monofocal IOLs is identical; 
thus, the higher frequency of posterior capsule opacity 
in the multifocal group was not related to its shape. 
TABLE 2
Vision-Related Quality of Life
Multifocal Group (n = 108) Monofocal Group (n = 98) Between-Group Differencea
Characteristic No. LS Mean (SE) No. LS Mean (SE) LS Mean (SE) 95% CI P
Primary endpoints
  Near vision 100 87.6 (1.9) 93 83.6 (2.0) 4.1 (2.3) -0.5 to 8.7 .2508
  Activity limitations 99 95.2 (1.4) 90 94.9 (1.5) 0.3 (1.8) -3.2 to 3.84 .8515
  Dependence on correction 99 83.7 (3.5) 92 46.3 (3.7) 37.3 (4.4) 28.7 to 46.0 < .0001
  Appearance 98 84.5 (2.7) 90 76.8 (2.9) 7.7 (3.4) 1.0 to 14.4 .0998
  Satisfaction with correction 98 84.8 (2.1) 90 82.4 (2.2) 2.4 (2.6) -2.7 to 7.5 .7040
Exploratory endpoints
  Clarity of vision 99 83.2 (2.2) 93 85.2 (2.3) -2.1 (2.8) -7.5 to 3.4 .4601
  Expectations 100 69.1 (4.0) 93 54.2 (4.3) 14.9 (5.1) 4.8 to 24.9 .0039
  Far vision 100 85.0 (1.8) 93 88.2 (1.9) -3.2 (2.2) -7.6 to 1.1 .1436
  Diurnal fluctuations 100 85.5 (2.6) 93 80.3 (2.7) 5.1 (3.2) -1.3 to 11.5 .1163
  Glare 100 69.0 (3.1) 93 78.5 (3.3) -9.6 (3.9) -17.3 to -1.8 .0157
  Symptoms 100 82.1 (2.0) 93 79.4 (2.1) 2.7 (2.5) -2.3 to 7.7 .2839
  Worry 99 76.4 (3.4) 92 74.4 (3.6) 2.0 (4.2) -6.4 to 10.4 .6400
  Suboptimal correction 97 96.4 (1.5) 90 97.8 (1.5) -1.4 (1.8) -5.0 to 2.2 .4552
CI = confidence interval; LS = least squares; monofocal group = commercially available nontoric monofocal intraocular lens group; multifocal group = AcrySof IQ 
ReSTOR or AcrySof IQ ReSTOR toric intraocular lens (Alcon Laboratories, Fort Worth, TX) group; SE = standard error 
aMultifocal IOL group score minus monofocal IOL group score.
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Furthermore, rates of posterior capsule opacification 
were not significantly different between the monofocal 
and multifocal IOL groups. As described above, self-
reported scores for glare were worse in the multifocal 
IOL group compared with the monofocal group.
At the 6-month visit, 75.5% (160 of 212) of eyes in 
the multifocal IOL group and 77.7% (153 of 197) of 
eyes in the monofocal IOL group achieved a refraction 
outcome within 0.5 D of target refraction. In the mul-
tifocal group, 81.1% received toric IOLs (86 of 106). 
The percentage of eyes within 1.0 D of target refraction 
was 91.0% and 91.4% for the multifocal and monofo-
cal groups, respectively. Refraction was measured as 
sphere plus (0.5 × cylinder), with the target being zero. 
DISCUSSION
The standard of care for treatment of cataract in-
volves removal of the crystalline lens and subsequent 
implantation of a nontoric monofocal IOL. Despite 
improvements in surgical techniques and outcomes, 
patients often require multifocal spectacles for near 
visual acuity and residual astigmatic error after sur-
gery.3 Postoperative dependence on vision correction 
is one of several factors that contribute to diminished 
vision-related quality of life after cataract surgery. The 
goal of this study was to evaluate and compare visual 
outcomes, spectacle independence, and quality of life 
among nonastigmatic and astigmatic patients who re-
ceived AcrySof IQ ReSTOR toric or nontoric multifocal 
IOLs compared with those who received commercially 
available monofocal IOLs following bilateral cataract 
removal. 
In this study, both toric and nontoric AcrySof mul-
tifocal IOLs were effective and well tolerated. Com-
pared with patients who received bilateral nontoric 
monofocal IOLs, patients who received either nontoric 
or toric multifocal IOLs had a significantly higher rate 
of improved combined uncorrected near and distance 
visual acuity in both eyes, a significantly higher rate of 
spectacle independence, and significantly better NEI 
RQL-42 scores for dependence on correction. There 
was also a significant difference in postoperative spec-
tacle cost that favored the multifocal IOL group versus 
the monofocal IOL group. The rates of adverse events 
and the proportions of patients achieving postopera-
tive spherical equivalent within 0.5 and 1.0 D of target 
refraction 6 months after surgery and IOL implantation 
were similar between groups. 
The results of the current study are consistent with 
those of a prospective, 6-month follow-up study of 
patients in Europe and South America who received 
bilateral AcrySof aspheric toric or nontoric multifocal 
IOLs after cataract extraction.13 In that study, patients’ 
subjective experience, satisfaction, and spectacle free-
dom were significantly improved with implantation 
of multifocal IOLs. After 6 months, 90% of patients 
reported no spectacle dependence,13 compared with 
approximately 73% of patients in the current study. 
Similarly, multifocal IOLs produced significant im-
provements in uncorrected visual acuity compared 
with preoperative levels13 and monofocal IOLs, re-
spectively. Our results also demonstrated that pre-
dictability of refractive outcome was similar between 
groups, indicating that the higher rate of postoperative 
spectacle dependence in patients who received mono-
focal IOLs could be attributed to a poor ability to fo-
cus across a range of distances, whereas patients who 
received multifocal IOLs had improved vision at far, 
intermediate, and near distances.
Lower contrast sensitivity and higher incidence 
of photic phenomena, such as halos and glare, have 
been reported with multifocal IOLs compared with 
monofocal IOLs,3,10 despite good vision over a range of 
distances and spectacle independence achieved with 
multifocal IOLs.14,15 At the 1-year follow-up visit of a 
randomized prospective clinical trial, halo and glare 
were reported to be more common with refractive 
multifocal IOLs compared with diffractive IOLs, and 
contrast sensitivity in patients with diffractive multi-
focal IOLs was similar or superior to that in patients 
who received monofocal IOLs or refractive multifocal 
IOLs.14 However, similar to the current study, implan-
tation with diffractive multifocal IOLs was associated 
with greater spectacle independence. The findings of 
the current study demonstrated significantly higher in-
cidence of glare with multifocal IOLs compared with 
monofocal IOLs, although the difference was only 
approximately 14%, suggesting a clinically relevant 
complication for both groups. Despite the increased 
glare, patient satisfaction was high in the multifocal 
IOL group. 
Using a combination of clinical observations and 
modeling, studies conducted in Europe previously 
showed that patients receiving AcrySof multifocal 
IOLs achieved higher rates of spectacle independence, 
and therefore postoperative lower cost burdens, com-
pared with patients who received monofocal IOLs.7,16 
An open-label multicenter study of U.S. patients simi-
larly found that multifocal IOLs lead to higher rates 
of spectacle independence than monofocal IOLs; 
this work also estimated a net 14-year cost benefit of 
nearly $12,000 (U.S.) with multifocal IOLs compared 
with $155 with monofocal IOLs.4 In the current study, 
the total cost of spectacles was significantly higher in 
the monofocal IOL group, with costs for lenses alone 
nearly 75% higher than in the multifocal IOL group. 
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This was likely because patients who received mono-
focal IOLs required higher technology lenses such as 
bifocals to provide good vision at different distances. 
Together with the better score in the dimension of de-
pendence on correction in the multifocal IOL group, 
these data suggest that AcrySof multifocal IOLs could 
provide a long-term cost benefit for patients after cata-
ract surgery. 
Toric IOLs were available to patients with astigma-
tism receiving multifocal IOLs. At the time of the trial, 
no computerized devices were available for multifo-
cal toric IOL alignment. In our experience with pa-
tients implanted with multifocal toric IOLs, spectacle 
independence is closely related to IOL alignment. 
With the availability of newer technologies that op-
timize alignment and centration of multifocal toric 
IOLs, post-implantation outcomes may be even better 
than those observed in the current study. A limitation 
of this study is the need for a more detailed analysis 
of efficacy and safety outcomes in patients receiving 
toric versus nontoric IOLs and in patients receiving 
multifocal versus monofocal toric IOLs. Patients in 
the monofocal group received only nontoric IOLs; 
as such, visual outcomes may have been influenced 
by uncorrected astigmatism in these patients. How-
ever, this influence may have been negligible because 
uncorrected distance visual acuity of 20/40 or better 
at 6 months was achieved by 92% of patients receiv-
ing multifocal IOLs and by 97% of patients receiv-
ing monofocal IOLs. Additionally, cost assessments 
accounted only for postoperative spectacle costs; the 
costs associated with premium versus standard IOLs 
were not addressed. No adjustment was made for mul-
tiple testing correction for nonprimary endpoints. In 
some instances the questionnaires were not reviewed 
for completeness, which resulted in responses being 
ambiguous or missing. Methods for dealing with miss-
ing data were prespecified in the statistical analysis 
plan, and data handling conventions were defined to 
best accommodate instances where more than one re-
sponse was entered for each question. 
Patients with or without astigmatism and who re-
ceived nontoric or toric AcrySof IQ ReSTOR IOLs fol-
lowing phacoemulsification cataract removal had sig-
nificantly better visual acuity response rates and better 
overall vision-related quality of life (eg, spectacle inde-
pendence, dependence on correction) compared with 
patients who received nontoric monofocal IOLs. Mono-
focal IOLs were associated with better patient-reported 
scores for glare compared with multifocal IOLs; how-
ever, scores for patient expectations were significantly 
better in the multifocal IOL group. Both the multifocal 
and monofocal IOLs were well tolerated.
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TABLE A
Postoperative Spectacle Cost
Cost (Euros) Monofocal Group (n = 98) Multifocal Group (n = 108)
Total cost of spectacles (lenses + frames)
  All patients
    No. 101 95
    Mean ± standard deviation 151.50 ± 236.84 40.12 ± 111.80
    Median 85.73 0.00
  Spectacle-dependent patientsa
    No. 55 19
    Mean ± standard deviation 224.41 ± 276.86 178.36 ± 203.99
    Median 117.95 96.00
Lensesa
  No. 32 13
  Mean ± standard deviation 267.21 ± 258.26 154.42 ± 170.13
  Median 170.00 90.00
Framesa
  No. 27 10
  Mean ± standard deviation 74.35 ± 84.79 66.59 ± 103.70
  Median 45.00 25.25
Monofocal group = commercially available nontoric monofocal intraocular lens group; multifocal group = AcrySof IQ ReSTOR or AcrySof IQ ReSTOR toric intraocu-
lar lens (Alcon Laboratories, Fort Worth, TX) group 
aData reflect patients who reported cost information.
TABLE B
Adverse Events
Characteristic
Multifocal Group 
(n = 106)
Monofocal Group 
(n = 100)
No. of patients with ≥ 1 
AEs (%)
43 (40.6) 30 (30.0)
Total no. of AEs 73 77
No. of patients with ≥ 1 
serious AE (%)
13 (12.3) 9 (9.0)
No. of serious AEs (%)
  Posterior capsule 
opacification
2 (1.9) 0
  Astigmatism 1 (0.9) 0
  Corneal edema 1 (0.9) 0
  Cystoid macular edema 1 (0.9) 0
  Lens dislocation 1 (0.9) 0
  Retinal tear 1 (0.9) 0
  Vitreous loss 1 (0.9) 0
  Leukemia 1 (0.9) 0
  Cardiac disorder 1 (0.9) 0
  Intestinal functional 
disorder
1 (0.9) 0
  Endophthalmitis 1 (0.9) 0
  Intraocular pressure 
increased
1 (0.9) 0
  Nephrolithiasis 1 (0.9) 0
  Iridocele 0 1 (1.0)
  Photophobia 0 1 (1.0)
  Retinal detachment 0 1 (1.0)
  Vitreous detachment 0 1 (1.0)
  Vitritis 0 1 (1.0)
  Malignant lung neoplasm 0 1 (1.0)
  Neuroma 0 1 (1.0)
  Device material issue 0 1 (1.0)
  Eye operation  
complication
0 1 (1.0)
  COPD 0 1 (1.0)
AE = adverse event; monofocal group = commercially available nontoric 
monofocal intraocular lens group; multifocal group = AcrySof IQ ReSTOR 
or AcrySof IQ ReSTOR toric intraocular lens (Alcon Laboratories, Fort Worth, 
TX) group; COPD = chronic obstructive pulmonary disease
